Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...

The FDA has accepted Pharming Group’s supplemental new drug application for leniolisib in treating activated phosphoinositide ...

There are steps physicians can take to prepare their patients with pulmonary issues for the changing of the seasons.